Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Insulin resistance plays a key role in the pathogenesis of polycystic ovarian syndrome (PCOS). One of the methods for correcting insulin resistance is using myo-inositol. AIM: The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance. PATIENTS AND METHODS: This study included 50 anovulatory PCOS patients with insulin resistance. All of them received myo-inositolduring three spontaneous cycles. If patients remained anovulatory and/or no pregnancy was achieved, combination of myo-inositol and clomiphene citrate was used in the next three cycles. Ovulation and pregnancy rate, changes in body mass index (BMI) and homeostatic model assessment (HOMA) index and the rate of adverse events were assessed. RESULTS: After myo-inositol treatment, ovulation was present in 29 women (61.7%) and 18 (38.3%) were resistant. Of the ovulatory women, 11 became pregnant (37.9%). Of the 18 myo-inositol resistant patients after clomiphene treatment, 13 (72.2%) ovulated. Of the 13 ovulatory women, 6 (42.6%) became pregnant. During follow-up, a reduction of body mass index and HOMA index was also observed. CONCLUSION: Myo-inositol treatment ameliorates insulin resistance and body weight, and improves ovarian activity in PCOS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197
RetractedLegro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“studies, PCOS patients have an increased risk for diabetes mellitus [3,6] and often show an adverse cardiovascular risk profile – increased rate of arterial hypertension [7,8], dislipidemia [9–12] and subclinical inflammation and atherosclerosis [13–15] – that”
BackgroundVelazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“Many studies [30,31] demonstrate a beneficial effect of metformin and”
BackgroundNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 3×
“[34] showed a non-significant change of BMI – from 29 ± 1.”
BackgroundMethodSelf-citationEffects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154 · cited 1×
“[36] demonstrated the relevant effect of Myo-inositol administration”
BackgroundInsulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Raffone, E., Rizzo, P., & Benedetto, V. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903366996 · Cited by 100 · cited 1×
“[22], in a comparative study for ovulation induction between myo-inositol and metfor-”
Background
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“, patients responding to myo-Ins supplementation showed significantly lower testosterone levels, higher SHBG and lower free androgen index [172], while in another study by Kamenov and colleagues most of the patients resistant to myo-Ins therapy were obese women [173].”
ResultSelf-citationInositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Self-citationKamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
“[104] most of the patients resistant to MI were obese.”
BackgroundSelf-citationFacchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Self-citation
Metadata
- Authors
- Kamenov, Z., Kolarov, G., Gateva, A., Carlomagno, G., & Genazzani, A. D.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2014-09-26
- Volume
- 31
- Issue
- 2
- Pages
- 131-135
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2058939731
- Cited by
- 80
- References
- 9
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. https://app.cochat.ai/papers/10.3109/09513590.2014.964640
- The paper
- Kamenov, Z., Kolarov, G., Gateva, A., Carlomagno, G., & Genazzani, A. D. (2015). Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2014.964640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.